Last reviewed · How we verify
NCT02355899
Evaluation of the Suitability of PD P 506 A in the Photodynamic Therapy of Distal Subungual Onychomycosis (DSO) of the Great Toenail.
Phase 2 trial testing PD P 506 A in Onychomycosis in 25 participants. Completed in 23 August 2017.
23 August 2017
Quick facts
| Lead sponsor | photonamic GmbH & Co. KG |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 January 2015 |
| Primary completion | 23 August 2017 |
| Estimated completion | 23 August 2017 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- PD P 506 A — full drug profile →
Conditions studied
- Onychomycosis — all drugs for Onychomycosis →
Sponsor
photonamic GmbH & Co. KG — full company profile →
Who can join
Adults 18 to 75, any sex, with Onychomycosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Percentage of nails with Clinically Complete Cure
Time frame: 12 months after last study treatment
The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad
Sponsor's own description
This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail. Patients will receive four PDT treatments with PD P 506 A in weekly intervals.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies.
Youf R, Müller M, Balasini A, Thétiot F, et al · · 2021 · cited 95× · PMID 34959277 · DOI 10.3390/pharmaceutics13121995
Verify or expand the search:
- PubMed search for NCT02355899
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PD P 506 A
Trials testing the same drug.
- NCT03606122 — 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities · Phase 2 · completed
Other recruiting trials for Onychomycosis
Currently open trials in the same condition.
- NCT06327295 — A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis · Phase 2 · recruiting
- NCT05482763 — Mycosis Culture Collection From Dermatological Isolated · active not recruiting
Other photonamic GmbH & Co. KG trials
Trials by the same sponsor.
- NCT03606122 — 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities · Phase 2 · completed
- NCT01110954 — Fluorescence-guided Resection in Breast Cancer · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02355899 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by photonamic GmbH & Co. KG
- Last refreshed: 18 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02355899.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing